Ross\Johnson & Associates’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-3
Closed -$163 – 296
2026
Q2
$163 Buy
+3
New +$146 ﹤0.01% 244
2025
Q2
– Sell
-40
Closed -$1.48K – 254
2025
Q1
$1.48K Buy
+40
New +$1.42K 0.03% 187

Other funds holding EXEL

Ross\Johnson & Associates's EXEL Position: Q3 2026 in Review

Ross\Johnson & Associates sold out of Exelixis (EXEL) in Q3 2026, closing a stake of 3 shares — an estimated $163 sold.

Ross\Johnson & Associates first reported a position in EXEL in Q1 2025 and held it in 2 quarters. The position peaked at $1.48K in Q1 2025. 775 funds tracked by Wall St. Rank hold EXEL as of Q3 2026.

  • Ross\Johnson & Associates reported no remaining Exelixis position as of Q3 2026 after selling out during the quarter.
  • Ross\Johnson & Associates sold 3 Exelixis shares in Q3 2026, an estimated $163.
  • Ross\Johnson & Associates first reported a position in Exelixis in Q1 2025 and held it in 2 quarters.
  • Ross\Johnson & Associates's Exelixis position peaked at $1.48K in Q1 2025.
  • 775 funds tracked by Wall St. Rank held Exelixis as of Q3 2026.

Based on Ross\Johnson & Associates's 13F filing for Q3 2026, filed 16 Nov 2026.